AMSTERDAM, Sept 2: An experimental drug from Isis Pharmaceuticals produced a sharp reduction in levels of triglycerides, a type of fat in the blood that increases the risk of heart disease, a small mid-stage trial showed. Codenamed ISIS-APOCIIIRx, the drug is attracting increased attention from investors who believe it could be a big money spinner for the US biotech company. It is designed for patients with very high to severely high triglyceride levels. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel